Haemonetics HAE Business Segments
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Net revenues by Business | ||||||
| Blood Center | $56.41M-0.3% | $56.56M+0.2% | $56.45M+8.9% | $51.84M-7.4% | $56.01M-20.4% | |
| Hospital | $159.65M+11.3% | $143.5M-1.4% | $145.5M+4.2% | $139.66M-5.5% | $147.86M+2.7% | |
| Plasma | $130.29M-6.2% | $138.91M+10.8% | $125.36M-3.5% | $129.9M+2.5% | $126.74M-5.6% | |
| Operating Income by Business | ||||||
| Blood Center | $11.24M-13.7% | $13.03M-12.1% | $14.83M+36.1% | $10.89M+9.8% | $9.92M-30.8% | |
| Hospital | $29.57M+14.1% | $25.92M-13.2% | $29.86M+62.5% | $18.38M-15.7% | $21.79M-20.4% | |
| Plasma | $43.69M-13.0% | $50.23M+17.9% | $42.59M-11.8% | $48.29M-4.6% | $50.63M+6.1% | |
| Costs incurred, net of reversals by Business | ||||||
| Blood Center | -$22K-103% | $822K+343% | -$338K+66.9% | -$1.02M-304% | $501K-26.9% | |
| Hospital | $95K-17.4% | $115K-78.7% | $540K-6.3% | $576K+122% | $260K-66.4% | |
| Plasma | $0+100% | -$43K+44.2% | -$77K-114% | $568K— | —— | |
| SG&A by Business | ||||||
| Blood Center | $13.48M0.0% | $13.47M-0.2% | $13.5M-1.3% | $13.68M-8.2% | $14.91M+4.2% | |
| Hospital | $67.03M+11.8% | $59.94M+3.4% | $57.97M-7.0% | $62.32M-0.5% | $62.63M+5.9% | |
| Plasma | $27.27M+0.6% | $27.1M+9.4% | $24.76M-5.5% | $26.2M+7.0% | $24.49M+4.1% | |
| Cost of goods sold by Business | ||||||
| Blood Center | $30.67M+5.4% | $29.1M+8.0% | $26.95M+3.9% | $25.95M-12.9% | $29.79M-26.0% | |
| Hospital | $54.59M+11.2% | $49.1M-0.4% | $49.32M-1.8% | $50.22M-7.7% | $54.42M+11.8% | |
| Plasma | $54.39M-4.3% | $56.81M+7.1% | $53.02M+6.2% | $49.92M+5.5% | $47.33M-19.3% | |
| Total long-lived assets by Business | ||||||
| Blood Center | $39.68M-4.0% | $41.33M+4.8% | $39.46M+2.7% | $38.41M-4.8% | $40.34M— | |
| Hospital | $59.72M+24.3% | $48.06M-13.1% | $55.3M+1.1% | $54.71M+1.5% | $53.88M— | |
| Plasma | $206.37M-0.7% | $207.84M+1.8% | $204.26M+5.4% | $193.74M+2.1% | $189.83M— | |
| R&D by Business | ||||||
| Blood Center | $1.03M+6.6% | $966K-17.9% | $1.18M-10.8% | $1.32M-5.6% | $1.4M-5.4% | |
| Hospital | $8.46M-0.9% | $8.54M+2.2% | $8.35M-4.5% | $8.74M-3.0% | $9.01M+2.8% | |
| Plasma | $4.94M+3.5% | $4.77M-4.4% | $4.99M-9.2% | $5.5M+28.4% | $4.28M-0.5% | |
| Restructuring related costs by Business | ||||||
| Blood Center | $0+100% | -$1K— | $0— | $0-100% | $34K+9.7% | |
| Hospital | $0— | $0— | $0— | $0-100% | $103K+251% | |
| Plasma | $0— | $0— | $0-100% | $9K-50.0% | $18K-51.4% | |
| D&A by Business | ||||||
| Blood Center | $1.79M0.0% | $1.79M0.0% | $1.79M0.0% | $1.79M-28.9% | $2.52M0.0% | |
| Hospital | $14.3M0.0% | $14.3M0.0% | $14.3M0.0% | $14.3M-0.1% | $14.31M0.0% | |
| Plasma | $11.84M0.0% | $11.84M0.0% | $11.84M0.0% | $11.84M-1.9% | $12.07M0.0% | |
| Currency translation by Business | ||||||
| Blood Center | -$89K— | —— | —— | $240K— | —— | |
| Plasma | $0— | $0— | $0— | $0— | $0— | |
| Goodwill by Business | ||||||
| Blood Center | $26.89M-0.3% | $26.98M-0.4% | $27.09M-0.4% | $27.21M+0.9% | $26.97M-6.2% | |
| Hospital | $600.44M+9.0% | $550.81M+0.2% | $549.97M-0.2% | $551.05M+0.5% | $548.26M+0.1% | |
| Plasma | $29.04M0.0% | $29.04M0.0% | $29.04M0.0% | $29.04M0.0% | $29.04M0.0% | |
| Total net revenues by Product | ||||||
| Plasma | $130.29M-6.2% | $138.91M+10.8% | $125.36M-3.5% | $129.9M+2.5% | $126.74M-5.6% | |
| Net revenues by Geography | ||||||
| Europe | $52.9M+9.6% | $48.28M+12.4% | $42.97M+5.1% | $40.88M-3.3% | $42.28M-4.3% | |
| Japan | $18.4M+1.5% | $18.14M+0.7% | $18.01M+32.0% | $13.65M-15.3% | $16.11M-0.4% | |
| Other | $3.11M+71.8% | $1.81M-50.8% | $3.68M+31.0% | $2.81M+1.5% | $2.77M-43.9% | |
| Rest of Asia | $19.97M-13.3% | $23.03M+2.0% | $22.57M+4.2% | $21.65M+2.3% | $21.16M-17.3% | |
| United States | $251.97M+1.7% | $247.71M+3.2% | $240.09M-1.0% | $242.4M-2.4% | $248.29M-3.6% | |
| Total long-lived assets by Geography | ||||||
| Europe | $32.08M+4.3% | $30.77M+21.7% | $25.29M+4.6% | $24.18M+20.7% | $20.02M— | |
| Japan | $916K-12.3% | $1.05M-12.6% | $1.2M-2.7% | $1.23M-1.8% | $1.25M— | |
| Other | $17.23M-4.4% | $18.03M+0.6% | $17.93M+0.7% | $17.8M+5.6% | $16.86M— | |
| Rest of Asia | $30.83M-2.3% | $31.54M+1.9% | $30.94M+3.7% | $29.83M+3.9% | $28.71M— | |
| United States | $224.7M+4.1% | $215.85M-3.5% | $223.66M+4.6% | $213.83M-1.6% | $217.21M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Haemonetics break its business down?
- Haemonetics (HAE) reports net revenues by business across 3 parts — Blood Center, Hospital and Plasma. Each is extracted from the segment footnotes and tracked over time.
- Where does Haemonetics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Haemonetics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.